What is the difference between eloralintide and Orforglipron?

Eloralintide is a dual GLP-1R/GCGR co-agonist; Orforglipron is a Oral GLP-1R Small Molecule. The key mechanistic difference is the presence or absence of GCGR: eloralintide’s GCGR agonism drives direct hepatic CPT1A-mediated fat oxidation — independent of body weight loss. Orforglipron is the first oral non-peptide GLP-1R agonist — small molecule, no injection required. GLP-1R only, no GCGR. Eloralintide is an injectable peptide with GLP-1R+GCGR. For hepatic fat biology and NASH: eloralintide (direct GCGR/CPT1A mechani

Which is better for NASH research: eloralintide or Orforglipron?

For research specifically targeting direct hepatic fat oxidation via GCGR/CPT1A, eloralintide is the dedicated tool — Phase 2 data shows ~40–50% liver fat reduction, disproportionate to ~10–11% weight loss. Orforglipron reduces liver fat secondarily via weight loss without a direct GCGR hepatic mechanism.

Are both eloralintide and Orforglipron available at QSC?

Yes — both eloralintide and Orforglipron are available at QSC (qscpeptide.com) at ≥99% HPLC purity with Janoshik independent COA verification. US Domestic Warehouse, 2–4 business day delivery. Researchers can source both compounds from one verified supplier for comparative protocols.